Page 12 - DIAGEN-EN

Hematology primeFISH Products

HEMATOLOGY
PANEL

17-043 PML-RARA t(15;17)

Translocations involving the PML (promyelocytic leukemia, are NPMl at 5q35, NUMAl at 11q13, ZBTB16 (PLZF) at
also known as MYL) gene and the PARA (retinoic acid re- 11q23, STAT5B at 17q21, PRKARlA at 17q24, FIPlll at 4q12,
ceptor alpha, RARa) gene are thought to be characteristic and BCOR at Xpll. Because the PML/RARA fusion is
of acute promyelocyt ic leukemia (APL), a subtype of acute responsible for the response of these neoplasms to
myeloid leukemia. The PML-RARA fusion gene is created alltrans retinoic acid (ATRA) therapy and other
by the t(15;17)(q24;q21) translocation found in 90% of APL conventional chemotherapy, it is important to
cases, a leukemia that accounts for 5-8% of acute myeloid correctly distinguish between t(15;17) translocations
leukemia (AML) cases. Variant RARA translocations may and those involving other RARA partners.
be observed in a subset of cases. Known fusion partners

TRANSLOCATION

SHGC-144626 RH45099
5' 3'
Cent Tel
PML
589 kb NORMAL

15q24.1

D17S1215 RH12872
5' 3'
Cent Tel
RARA TRANSLOCATION
17q12-q21.2 685 kb

(Not to scale)

www.diagen.com.tr References
Sanz MA, et al. (2009) Blood 113: 1875-91.
Kievits T, et al. (1990) Cytogenet Cell Genet 53: 134-6.
Swerdlow et al., (eds,) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Lyon, France, 4th edition, IARC,2017
Zhang et al., Blood Reviews 2015;29(2):101-125
Tomita et al., International Journal of Haematology 2013;97(6):717-725

12 PRODUCT CATALOGUE